Tumor cell ferroptosis in antitumor immunity and immunotherapy efficacy
Journal for ImmunoTherapy of Cancer · 2026-06 · 14 (6) · e014762
DOI: 10.1136/jitc-2025-014762 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 19.06.2026. Verfasst von Shuyin Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Ferroptosis, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Division of Cancer Prevention, National Cancer Institute.
Abstract (Originalsprache)
Cancer immunotherapy, particularly immune checkpoint blockade (ICB), has represented a major advancement for the treatment of various cancers. Though ICB has been an effective tool in the clinical management of patients, a significant subset of individuals do not respond clinically. This observation has motivated deeper investigations into the mechanisms of efficacy versus resistance to ICB. Of these, tumor cell-intrinsic mechanisms, such as the activation of immune regulatory oncogene pathways or immune selection for antigen-loss variants, have been a promising focus of study. Recent evidence has emerged that ferroptosis, a tumor cell-intrinsic cell death pathway, plays an important role in CD8 + T cell-mediated tumor cell killing, and that some resistant tumors have lost sensitivity to this process. Ferroptosis is an iron-dependent mechanism of cell death that is mediated by the peroxidation of lipids. Tumor cell-intrinsic regulators govern ferroptosis sensitivity and, in turn, can influence the success of immune-mediated tumor control. Here, we discuss the growing understanding of regulation of ferroptosis and examine the complex interplay between tumor cell-intrinsic ferroptosis pathways and the host immune response, with an emphasis on how ferroptosis might be leveraged to potentiate immunotherapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, The University of Chicago, Chicago, Illinois, USA.
- Department of Medicine and the Ben May Department of Cancer Research, The University of Chicago, Chicago, Illinois, USA tgajewsk@bsd.uchicago.edu.
Förderung
- NCI NIH HHS
- Division of Cancer Prevention, National Cancer Institute
Zitieren
APA
Li, S., & Gajewski, T. (2026). Tumor cell ferroptosis in antitumor immunity and immunotherapy efficacy. Journal for ImmunoTherapy of Cancer, 14(6), e014762. https://doi.org/10.1136/jitc-2025-014762
Vancouver
Li S, Gajewski T. Tumor cell ferroptosis in antitumor immunity and immunotherapy efficacy. Journal for ImmunoTherapy of Cancer. 2026;14(6):e014762. doi:10.1136/jitc-2025-014762
BibTeX
@article{Li2026,
author = {Li, Shuyin and Gajewski, Thomas},
title = {Tumor cell ferroptosis in antitumor immunity and immunotherapy efficacy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {6},
pages = {e014762},
doi = {10.1136/jitc-2025-014762}
}
EUVIMED